Please assess the completion status of the following clinical trial:

Trial Title: Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must have signed a written informed consent form prior to any study specific procedures~2. Patients aged ≥18 years old~3. Histologically confirmed diagnosis of gastro-oesophageal adenocarcinomas: gastroesophageal junction (Siewert II and III) and gastric adenocarcinomas~4. Asymptomatic primary tumour~5. Metastatic disease~6. At least one target lesion (according to RECIST v1.1):~   * Unidimensionally measurable on cross-sectional imaging~  * In an area not previously irradiated~7. Disease progression after a fluoropyrimidine and platinum agent-based chemotherapy (5-fluorouracil or 5-fluorouracil prodrugs combined with cisplatin or oxaliplatin). For example, docetaxel combined with FOLFOX, PD-L1/PD-1 inhibitors combined with FOLFOX, LV5-FU2-cisplatin or 5-fluorouracil-cisplatin are acceptable prior therapies.~8. Eastern Cooperative Oncology Group (ECOG) performance status ≤1~9. Life expectancy \>3 months~10. Amylase ≤1.5 x upper limit of normal (ULN) and lipase ≤1.5 x ULN~11. Adequate liver function:~    * Total bilirubin ≤1.5 x ULN~   * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN (≤5 x ULN for patients with liver metastasis)~   * Alkaline phosphatase (ALP) ≤2.5 x ULN (≤5.0 x ULN for patients with liver or bone metastases)~12. Platelet count ≥100,000/mm³; haemoglobin (Hb) ≥9 g/dL; absolute neutrophil count (ANC) ≥1,500/mm³. The use of blood transfusion(s) to meet the inclusion criteria will not be allowed~13. International normalised ratio (INR) ≤1.5 x ULN and partial thromboplastin time (PTT) or activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless receiving treatment with therapeutic anticoagulation. Patients being treated with anticoagulant, e.g., heparin, are eligible if there is no evidence of an underlying abnormality with these parameters and if a close monitoring of at least weekly evaluations was performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care~14. Creatinine clearance (CLcr) ≥50 mL/min estimated by Cockcroft-Gault equation~15. Women of childbearing potential and men must agree to use adequate contraception during the study and for at least 3 months after the last study drug administration~16. Patients affiliated to the social security system~Exclusion Criteria:~1. Symptomatic brain metastases or carcinomatous meningitis~2. Bone-only metastasis~3. Known and documented UGT1A1 deficiency~4. History of Gilbert's syndrome~5. Previous or concurrent cancer with a distinct primary site, other than gastro-oesophageal cancer, within 5 years prior to randomisation (except for curatively treated cervical cancer in situ, non-melanoma skin cancer, and superficial bladder tumours)~6. Persistent proteinuria \>3.5 g/24 h measured by urine protein-creatinine ratio from a random urine sample (grade ≥3, NCI-CTCAE v 5.0)~7. Interstitial lung disease with ongoing signs and symptoms at inclusion~8. Known hypersensitivity to any of the study drugs, study drug classes, or excipients~9. Non-healing wound, non-healing ulcer, or non-healing bone fracture~10. Patients with evidence or history of any bleeding diathesis, irrespective of severity~11. Any haemorrhage or bleeding event grade ≥3 (NCI-CTCAE v.5.0) within 4 weeks before starting of the study treatment~12. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 month before starting the study treatment (except for adequately treated catheter-related venous thrombosis occurring more than one month before the start of study medication)~13. Previous major surgical procedure, significant traumatic injury, or radiotherapy within the 4 weeks before inclusion~14. Uncontrolled hypertension (systolic blood pressure \>140 mmHg or diastolic pressure \>90 mmHg) despite optimal medical management. Congestive heart failure: New York Heart Association (NYHA) ≥ class 2~15. Unstable angina (angina symptoms at rest), new-onset angina (that started within the last 3 months)~16. Myocardial infarction less than 6 months before starting the study treatment~17. Uncontrolled cardiac arrhythmias~18. History of epileptic seizures requiring long-term anticonvulsant therapy~19. History of organ transplantation with use of immunosuppression therapy~20. Ongoing bacterial or fungal infection (grade \>2 by NCI-CTCAE v.5.0)~21. Known history of human immunodeficiency virus (HIV) infection~22. Active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy~23. Use of CYP3A4 inducers or inhibitors~24. Pregnant or breast-feeding women~25. Bowel malabsorption or extended bowel resection that could affect the absorption of regorafenib, occlusive syndrome, inability to take oral medications~26. Inflammatory bowel disease with chronic diarrhoea~27. Participation in another clinical trial within the 30 days before inclusion~28. Concurrent treatment with another investigational product or anticancer therapy (other than irinotecan or regorafenib)~29. Concomitant treatment with hypericum or live attenuated vaccines~30. Gastro-intestinal fistula or perforation~31. Person kept in detention or incapable of giving consent~32. Patient unwilling or unable to comply with the medical follow-up required by the study because of geographic, social, or psychological reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib and Irinotecan (Type: EXPERIMENTAL): Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle combined with regorafenib 160 mg daily on Day2-8 and D16-22 of a 4 week cycle administered until progression of disease or unacceptable toxicity.
- Irinotecan (Type: ACTIVE_COMPARATOR): Irinotecan 180 mg/m² on Day1 and Day 15 of a 4 week cycle administered until progression of disease or unacceptable toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).